iDose TR

Generic name: travoprost
Dosage form: intracameral implant (75 mcg)
Drug class: Ophthalmic glaucoma agents

Medically reviewed by Melisa Puckey, BPharm. Last updated on Mar 26, 2024.

What is iDose TR?

iDose TR (travoprost) is a long-acting eye implant used for open-angle glaucoma or ocular hypertension to lower pressure within the eye.  iDose TR works by slowly releasing travoprost, which increases the flow of a water-like fluid (aqueous humor) out of the eye, which decreases eye pressure (intraocular pressure).  iDose TR implants lasted for 3 years with continued intraocular pressure reductions in Phase 2b clinical trials.  iDose TR contains travoprost, which is a prostaglandin F2α analog. 

What is iDose TR used for?

iDose TR is used to lower intraocular pressure (IOP) in patients who have ocular hypertension (OHT) or open-angle glaucoma (OAG). The increase in eye pressure in OAG can cause loss of peripheral vision followed by central field blindness and increase the risk of vision loss in OHT.  iDose TR reduces the intraocular pressure to lower the risk of vision loss in OHT and reduce the progression of vision loss in OAG.

iDose TR side effects

Common iDose TR side effects include increases in eye pressure, inflammation of the colored part of the eye (iris), dry eye, and vision problems; these side effects happened to 2% to 6% of patients. 

Serious iDose TR side effects include macular edema, intraocular inflammation, color change to the iris that may be permanent, and inflammation of the inner coats of the eye due to infection of the intraocular fluid (endophthalmitis).

Seek immediate care from an ophthalmologist if the eye becomes red, sensitive to light, painful, or develops a change in vision.

Related/similar drugs

Warnings

• This implant  should be used with caution in patients with narrow angles or other angle abnormalities.
• Monitor patients routinely to confirm the location of the implant at the site of administration in case it has moved.
• Increased pigmentation of the iris (colored part of the eye)  can occur which is likely to be permanent.
• Magnetic Resonance Imaging (MRI). iDose TR is MR Conditional. This means that the implant does contain magnetic, conductive, or RF-reactive components but is deemed to be safe for use in the MRI environment if the conditions for safe use are met. If the patient requires magnetic resonance imaging (MRI), they should inform their healthcare provider that they have an iDose TR implanted in their eye. A patient with this implant may be safely scanned under conditions defined in the prescribing information. Failure to follow these conditions may result in injury to the patient. 

Who should not have iDose TR?

iDose TR should not be used for patients who have or are suspected of having an ocular or periocular infection, who have corneal endothelial dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), who have had corneal transplantation or have a hypersensitivity to travoprost or to any other components of the implant.

Before taking this medicine

Pregnancy

Tell your healthcare provider if you are pregnant or plan to become pregnant, as there is a potential risk to your baby.  iDose TR should be used during pregnancy only if the potential benefit justifies the potential risk to the baby.

Breastfeeding

Tell your healthcare provider if you are breastfeeding or planning to breastfeed, as the effects of travoprost on the breastfed child or milk production on breastmilk are not known.

How will I receive iDose TR?

iDose TR is an intracameral implant that is inserted into the eye by your fully trained healthcare provider.

This implant should not be readministered to an eye that has already had an iDose TR.

Dosing information

iDose TR implant contains 75 mcg travoprost, pre-loaded in a single-dose inserter.

What other drugs will affect iDose TR?

Tell your doctor about all your current medicines and any you start or stop using. Other drugs may interact with this implant, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Storage

• Store at 2°C to 25°C (36°F to 77°F).
• Do not freeze

Ingredients

Active ingredient: 75 mcg of travoprost. 

Intracameral implant: titanium implant reservoir with a membrane controlling the sustained release of travoprost. 

Company

Manufactured by Glaukos Corp., 229 Avenida Fabricante, San Clemente, CA 92672.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer